EPHA3 Specific Neutra™ Antibody Products

Ephrin receptor A3 (EPHA3) is a member of the EPH receptor tyrosine kinase family, encoded by the EPHA3 gene. It is vital in several physiological processes, including embryonic development, tissue patterning, and neuronal guidance. Structurally, EPHA3 comprises an extracellular domain for ligand binding, a transmembrane area, and an intracellular kinase domain. Interaction with its ligands, Ephrins, triggers bidirectional signaling, regulating cell adhesion, migration, and repulsion. Dysregulation of EPHA3 signaling has been implicated in cancer, neurodegenerative disorders, and other diseases, making it a potential therapeutic target for intervention.

Its Gene ID: 2042, UniProtKB ID: P29320, and OMIM ID: 179611.

Biological Roles of EPHA3

EPHA3 plays diverse biological roles across various tissues and developmental stages. In embryogenesis, it regulates cell migration, tissue patterning, and axon guidance, crucial for proper organogenesis and nervous system development. In the adult organism, EPHA3 contributes to tissue homeostasis, immune cell function, and synaptic plasticity in the brain. Dysregulation of EPHA3 signaling is associated with cancer progression, where it influences tumor growth, invasion, and metastasis. Moreover, EPHA3 is implicated in neurodegenerative diseases and inflammatory disorders, highlighting its significance in both normal physiology and pathological conditions.

EPHA3 in Cancer

EPHA3's function in tumors is multifaceted, with evidence suggesting both tumor-suppressive and tumor-promoting roles depending on the cancer type and context. In certain malignancies, EPHA3 acts as a tumor suppressor by decreasing cell proliferation, and suppressing metastasis through regulation of cell adhesion and migration pathways. Conversely, in other cancers, EPHA3 promotes tumor progression by facilitating angiogenesis, enhancing invasion, and promoting tumor cell survival. Research into EPHA3-related tumors has uncovered its significance in various cancer types, including glioblastoma, melanoma, lung cancer, and breast cancer. Studies have elucidated the molecular mechanisms underlying EPHA3 dysregulation in tumorigenesis, such as altered expression levels, genetic mutations, and epigenetic modifications.

Fig.1 The regulation of cellular processes by the EPH/Ephrin system.¹

Antibodies Targeting EPHA3

Therapeutic antibodies targeting EPHA3 have garnered attention for their possible use in cancer therapy. These antibodies function by binding to EPHA3, inhibiting EPHA3-dependent proliferation, modulating it signaling pathways, and influencing tumor cell behavior. One key application is in immunotherapy, where EPHA3-targeted antibodies can enhance immune-mediated tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Research progress has demonstrated promising results with EPHA3 therapeutic antibodies. For instance, in leukemia, EPHA3 antibodies promote leukemia cell death and reduce tumor burden by disrupting EPHA3-mediated anti-apoptotic pathways. Similarly, in preclinical models of glioblastoma, EPHA3 antibodies inhibit tumor growth and improve survival rates by blocking EPHA3-mediated pro-survival signaling.

Fig.2 Therapeutic mechanisms of anti-EPH receptor antibodies.²

Creative Biolabs offers highly specific anti-EPHA3 antibody products with high affinity to meet your diverse research needs.

REFERENCES

1. Shu, Xin, Qiang Wang, and Qingming Wu. "The Eph/Ephrin System in Hepatocellular Carcinoma: Functional Roles and Potential Therapeutic Targets." Oncologie (Tech Science Press) 24.3 (2022). Distributed under Open Access license CC BY 4.0, without modification.
2. Janes, Peter W., et al. "Antibody targeting of Eph receptors in cancer." Pharmaceuticals13.5 (2020): 88. Distributed under Open Access license CC BY 4.0, without modification.